Management of chronic myeloid leukemia in myeloid blastic phase with novel therapies: a systematic literature review.
Umut YılmazBatuhan BulanÇağrı BelliAhmet Emre EskazanPublished in: Expert review of hematology (2022)
Hypomethylating agent and TKI combination with or without the addition of venetoclax appear to be highly promising and have produced comparable outcomes with intensive chemotherapy and TKI combinations. Current evidence is insufficient to reach conclusions prompting dedicated research to improve the care of patients with CML-MBP.
Keyphrases
- chronic myeloid leukemia
- healthcare
- palliative care
- dendritic cells
- bone marrow
- quality improvement
- locally advanced
- acute myeloid leukemia
- chronic lymphocytic leukemia
- squamous cell carcinoma
- type diabetes
- immune response
- adipose tissue
- skeletal muscle
- metabolic syndrome
- glycemic control
- advanced non small cell lung cancer
- health insurance